CTLA4 and neoplasm: CD4+ naive/central-memory T cells from tdLN directly respond to anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA4) therapy, trafficking via blood to the tumor, where they acquire a Th1 phenotype (70).